Correction to "Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome"
- PMID: 41230536
- PMCID: PMC12602454
- DOI: 10.1002/jmd2.70049
Correction to "Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome"
Abstract
[This corrects the article DOI: 10.1002/jmd2.70041.].
© 2025 The Author(s). JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.
Erratum for
-
Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome.JIMD Rep. 2025 Aug 7;66(5):e70041. doi: 10.1002/jmd2.70041. eCollection 2025 Sep. JIMD Rep. 2025. PMID: 40778235 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
